Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

【作者(必填)】Weber J[size=0.8461em]1, Mandala M[size=0.8461em]1, Del Vecchio M[size=0.8461em]1, Gogas HJ[size=0.8461em]1, Arance AM[size=0.8461em]1, Cowey CL[size=0.8461em]1, Dalle S[size=0.8461em]1, Schenker M[size=0.8461em]1, Chiarion-Sileni V[size=0.8461em]1, Marquez-Rodas I[size=0.8461em]1, Grob JJ[size=0.8461em]1,Butler MO[size=0.8461em]1, Middleton MR[size=0.8461em]1, Maio M[size=0.8461em]1, Atkinson V[size=0.8461em]1, Queirolo P[size=0.8461em]1, Gonzalez R[size=0.8461em]1, Kudchadkar RR[size=0.8461em]1, Smylie M[size=0.8461em]1, Meyer N[size=0.8461em]1, Mortier L[size=0.8461em]1, Atkins MB[size=0.8461em]1, Long GV[size=0.8461em]1,Bhatia S[size=0.8461em]1, Lebbé C[size=0.8461em]1, Rutkowski P[size=0.8461em]1, Yokota K[size=0.8461em]1, Yamazaki N[size=0.8461em]1, Kim TM[size=0.8461em]1, de Pril V[size=0.8461em]1, Sabater J[size=0.8461em]1, Qureshi A[size=0.8461em]1, Larkin J[size=0.8461em]1, Ascierto PA[size=0.8461em]1; CheckMate 238 Collaborators.

【文题(必填)】[size=1.4em]Adjuvant[size=1.4em] [size=1.4em]Nivolumab[size=1.4em] [size=1.4em]versus[size=1.4em] [size=1.4em]Ipilimumab[size=1.4em] [size=1.4em]in[size=1.4em] [size=1.4em]Resected[size=1.4em] [size=1.4em]Stage[size=1.4em] [size=1.4em]III[size=1.4em] [size=1.4em]or[size=1.4em] [size=1.4em]IV[size=1.4em] [size=1.4em]Melanoma[size=1.4em].

【年份(必填)】2019

【全文链接或数据库名称(选填)】https://www.ncbi.nlm.nih.gov/pubmed/28891423